Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
- 1 February 2003
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 4 (2), 75-85
- https://doi.org/10.1016/s1470-2045(03)00979-3
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentBlood, 2002
- Treatment of hypereosinophilic syndrome with imatinib mesilateThe Lancet, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Autoinhibition of c-AblCell, 2002
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Crystallographic and Solution Studies of an Activation Loop Mutant of the Insulin Receptor Tyrosine KinasePublished by Elsevier BV ,2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivativesBioorganic & Medicinal Chemistry Letters, 1997